Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy.
Med
; 5(1): 1-3, 2024 Jan 12.
Article
en En
| MEDLINE
| ID: mdl-38218173
ABSTRACT
The PAPILLON trial showed that adding amivantamab to carboplatin-pemetrexed for advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations is more effective than chemotherapy. Although safety concerns may arise, this study highlights the need for alternative therapeutic strategies beyond chemotherapy for this subtype of NSCLC.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Biespecíficos
/
Carcinoma de Pulmón de Células no Pequeñas
/
Neoplasias Pulmonares
Límite:
Humans
Idioma:
En
Revista:
Med
Año:
2024
Tipo del documento:
Article